CytomX Logo PMS

About Us

CytomX is a clinical-stage, oncology-focused biopharmaceutical company developing its novel Probody®platform to enable drugging previously considered undruggable targets. Our pipeline includes potential first-in-class therapeutic candidates CX-2009, a wholly owned CD166-targeting Probody drug conjugate, and CX-2029, a CD71-targeting Probody drug conjugate partnered with AbbVie, both of which are in Phase 2. Our clinical-stage portfolio includes potential best-in-class immunotherapeutic candidates against clinically validated targetsOur strategic collaborations include AbbVie, Amgen, Astellas and Bristol Myers Squibb. 

Passport Stamp for World ADC San Diego 2022

Passport 2022 SD (7)

Team Members


Roland Gendron

Vice President, Business Development